← Back to Clinical Trials
Recruiting NCT07304947

NCT07304947 Cardiac Index-Guided Intraoperative Hemodynamic Management in Pediatric Moyamoya Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07304947
Status Recruiting
Phase
Sponsor Seoul National University Hospital
Condition Moyamoya Disease
Study Type INTERVENTIONAL
Enrollment 94 participants
Start Date 2025-12-02
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 1 Month
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
Cardiac Index-Guided Hemodynamic ManagementBlood Pressure-Guided Standard Hemodynamic Management

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 94 participants in total. It began in 2025-12-02 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This prospective randomized controlled trial evaluates whether individualized cardiac index-guided intraoperative hemodynamic management reduces postoperative transient ischemic episodes in pediatric patients undergoing encephaloduroarteriosynangiosis (EDAS) for Moyamoya disease. Patients are randomized 1:1 to goal-directed fluid therapy based on baseline cardiac index versus standard arterial pressure-based management. The primary outcome is the incidence of transient ischemic episodes during hospitalization.

Eligibility Criteria

Inclusion Criteria: * Pediatric patients \<18 years undergoing EDAS for Moyamoya disease under general anesthesia Exclusion Criteria: * ASA physical status 4-5 * Emergency surgery * Known cardiovascular disease * Any condition judged inappropriate by investigators

Contact & Investigator

Central Contact

Jung-Bin Park

✉ jb4001@snu.ac.kr

📞 820220723664

Frequently Asked Questions

Who can join the NCT07304947 clinical trial?

This trial is open to participants of all sexes, aged 1 Month or older, up to 18 Years, studying Moyamoya Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07304947 currently recruiting?

Yes, NCT07304947 is actively recruiting participants. Contact the research team at jb4001@snu.ac.kr for enrollment information.

Where is the NCT07304947 trial being conducted?

This trial is being conducted at Seoul, South Korea.

Who is sponsoring the NCT07304947 clinical trial?

NCT07304947 is sponsored by Seoul National University Hospital. The trial plans to enroll 94 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology